We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 304.00 | 303.00 | 305.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMHCM
RNS Number : 8508A
Hutchison China Meditech Limited
29 March 2017
Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 29, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that following the publication of the 2016 annual report of Chi-Med on March 27, 2017, the following awards granted under the Long Term Incentive Plan ("LTIP") on October 19, 2015 in respect of the annual performance targets for the financial year 2014 to Mr. Christian Hogg, Mr. Johnny Cheng and Dr. Weiguo Su were vested on March 28, 2017:-
Hot Features
Premium
Award Holders Number of Number of
Ordinary American depositary
Shares shares ("ADS")
Person Discharging Managerial
Responsibilities
Mr. Christian Hogg (Executive
Director and Chief Executive
Officer) 5,620 3,756
Mr. Johnny Cheng (Executive
Director and Chief Financial
Officer) Nil 4,626
Dr. Weiguo Su (Executive
Director and Chief Scientific
Officer) Nil 5,476
Total 5,620 13,858
========== =====================
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Mr Christian Hogg
----- ------------------------------------------------------- ------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Executive Officer
----- ------------------------------------------------------- ------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------------------------- ------------------------------------------------------
b) LEI N/A
----- ------------------------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
Description of the financial instrument, type of Ordinary Shares of US$1.00 each
a) instrument ADS each representing one half of one Ordinary Share
Identification code of US$1.00
DI ISIN: KYG4672N1016
ADS ISIN: US44842L1035
----- ------------------------------------------------------- ------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on October 19, 2015 in
respect of the annual performance targets
for the financial year 2014 under Chi-Med's LTIP
----- ------------------------------------------------------- ------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------------------
Nil 5,620 Ordinary Shares
--------- ----------------------
Nil 3,756 ADS
--------- ----------------------
----- ------------------------------------------------------- ------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----- ------------------------------------------------------- ------------------------------------------------------
e) Date of the transaction 2017-03-28
----- ------------------------------------------------------- ------------------------------------------------------
f) Place of the transaction London Stock Exchange (XLON) / Nasdaq Stock Market
----- ------------------------------------------------------- ------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Mr Johnny Cheng
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Financial Officer
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on October 19, 2015 in
respect of the annual performance targets
for the financial year 2014 under Chi Med's LTIP
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
Nil 4,626 ADS
--------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2017-03-28
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Dr Weiguo Su
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Scientific Officer
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on October 19, 2015 in
respect of the annual performance targets
for the financial year 2014 under Chi-Med's LTIP
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
Nil 5,476 ADS
--------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2017-03-28
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Investor Enquiries Christian Hogg, CEO +852 2121 8200 U.K. and International Media Enquiries Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKCDPABKKQNB
(END) Dow Jones Newswires
March 29, 2017 03:07 ET (07:07 GMT)
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
